Bluebird Bio

Bluebird Bio is a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer. The Company's clinical programs in severe genetic diseases include our LentiGlobin product candidate to treat transfusion dependent β-thalassemia and to treat severe sickle cell disease and itsLenti-D product candidate to treat cerebral adrenoleukodystrophy. Bluebird Bio programs in oncology are built upon its leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor and T cell receptor  T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. The Company also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies with the potential for use across its pipeline.

Company Growth (employees)
Cambridge, US
Size (employees)
339 (est)+4%
Bluebird Bio was founded in 1992 and is headquartered in Cambridge, US

Key People at Bluebird Bio

Nick Leschly

Nick Leschly

Jeffrey Walsh

Jeffrey Walsh

Chief Operating Officer

Bluebird Bio Office Locations

Bluebird Bio has offices in Cambridge and Seattle
Cambridge, US (HQ)
60 Binney St.
Seattle, US
208 1616 Eastlake Ave E

Bluebird Bio Data and Metrics

Bluebird Bio Financial Metrics

Bluebird Bio's revenue was reported to be $6.8 m in Q1, 2017

Revenue (Q1, 2017)

6.8 m

Net income (Q1, 2017)

(68.7 m)

EBIT (Q1, 2017)

(69.9 m)

Market capitalization (15-Sep-2017)

5.4 b

Cash (31-Mar-2017)

216 m
Bluebird Bio's current market capitalization is $5.4 b.
USDFY, 2013Y, 2014Y, 2015FY, 2016


20.2 m25.4 m14.1 m6.2 m

Revenue growth, %


R&D expense

204.8 m

General and administrative expense

65.1 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


6.3 m6.4 m6.3 m4.9 m1.3 m1.5 m1.6 m1.6 m6.8 m

R&D expense

13.9 m16.6 m23.7 m44.3 m30.4 m41.9 m41.8 m64 m55 m

General and administrative expense

5.7 m6.6 m7.3 m10.7 m13.7 m16 m18.4 m14.6 m20.3 m

Operating expense total

19.7 m23.3 m31.1 m55 m44.1 m57.9 m60.1 m78.6 m75.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


206.3 m347.8 m164.3 m278.9 m


5 m4.5 m6 m19.8 m

Current Assets

212 m480 m524 m724.2 m


10.9 m15.7 m82.6 m157 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


175.7 m89.6 m133.2 m593.3 m417.5 m192.6 m222.6 m245.2 m216 m

Current Assets

182.9 m223.3 m340.8 m815.5 m713.2 m561 m582.9 m608.8 m667.3 m


12.9 m15 m16.9 m16.8 m61.6 m96.6 m109.3 m131.7 m181.7 m


13.1 m13.1 m13.1 m13.1 m13.1 m13.1 m13.1 m13.1 m13.1 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(25.3 m)(48.7 m)(166.8 m)(263.5 m)

Depreciation and Amortization

941 k4.2 m7.4 m9.6 m


(14 m)

Accounts Payable

2.1 m(2.2 m)2.5 m6.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(1.5 m)(17 m)(24.8 m)(51.8 m)(42.9 m)(56.3 m)(58.8 m)(77 m)(68.7 m)

Accounts Payable

2.6 m3.6 m2.6 m2.3 m3.5 m3.1 m2.4 m6.7 m8.8 m
USDY, 2017


20.5 k

Financial Leverage

1.3 x
Show all financial metrics

Bluebird Bio Market Value History

Bluebird Bio Median Salaries

Source: 16 public H-1B filings from Bluebird Bio

Traffic Overview of Bluebird Bio

Bluebird Bio Online and Social Media Presence

Bluebird Bio News and Updates

Here's why Gilead broke its dealmaking hiatus and splurged $12 billion on a cancer treatment

Gilead Sciences bought cancer-immunotherapy company Kite Pharma for $11.9 billion Monday. The acquisition breaks a years-long hiatus from major dealmaking for Gilead. Sources say Gilead inked the deal because it was impressed by Kite's trial data and thought it had a strate…

Harnessing the U.S. Taxpayer to Fight Cancer and Make Profits

Public funding is backing a new immunotherapy treatment, but the bulk of any profits will go to a private company. So are taxpayers getting a good deal?

Donald Trump Sent Biotech Stocks Plummeting with These 16 Words

His drug price comments rattled investors.

Big Pharma Might Be Getting an Early Christmas Present

The 21st Century Cures Act looks like it's headed for a win.

Pharma Shares Drop After FDA Stops Cancer Therapy Trial for Patient Deaths

Juno Therapeutics was conducting the trial, but other firms also took a hit.

Bluebird Bio Company Life and Culture

You may also be interested in